

DF/HCC Mouse Engineering Core 77 Ave Louis Pasteur (NRB 837) Boston, MA 02115 617-432-6182 mouseengineeringcore@gmail.com Arlene H. Sharpe, M.D., Ph.D. Core Director

## Injection of DNA into Pronuclei

## CONTACT INFORMATION

Date:	Project Name:
Principal Investigator:	
Institution:	Department:
Address:	
Phone:	Email:
Lab Contact:	
Phone:	Email:

## ADDITIONAL INFORMATION

1.	Do	you receive industrial support for:	
	a.	any portion of your salary, or the salary of individuals working under your supervision, on the project in which the transgenic mouse will be used?	
	b.	the research project in which the transgenic mouse will be used? Yes No	
	C.	purchase of supplies, reagents, animals, tissues or cells which will be used in the research project for which the transgenic mouse is requested?	
2.		you have any active agreements with industry for the same scope of work for which the nsgenic mouse will be used?	
	If you answered "Yes" to Questions 1 or 2, please explain briefly:		

3.	Please indicate for-profit and/or non-profit sponsor(s), title, of research projects(s) and, if appropriate, grant numbers(s) of the on-going sponsored research project(s) in which the transgenic mouse will be used:	
4.	Will the transgenic mouse be used in conjunction with any other Material(s) received (not purchased) from another institution, company or any other third party?	
	If "Yes", please identify the other Material(s) and where it/they came from:	
	If "Yes", was there any Agreement, Statement of Investigator Form, letter of intent or correspondence of any kind between you and the provider of the Other Material(s) stating conditions, restrictions, or guidelines under which the Other Material(s) would be used?	
5.	Do you anticipate reporting the results generated from the studies using the transgenic mouse to any for-profit entity?	
	If "Yes", please identify the for-profit entity:	
6.	<b>Scientific Rational</b> – Briefly describe the specific aim of the study, the rational for using transgenic animals rather than other animal models. Are there any previous studies for which transgenics have been used?	٢
7.	<b>Animal Protocols</b> – Provide the appropriate protocol number(s) for project obtained from the Harvard Medical are Standing Committee for Animals.	a
8.	DNA Construct.	
	a. Vector carrying the construct:	
	b. Promoter: Species:	

c. Gene:

	d.	Construct is: CDNA Genomic DNA
	e.	Reporter: (if present)
	f.	Attach schematic diagram of the construct (Include restriction map, location and size of introns, exons, promoter, enhancer, etc.)
	g.	Identify the product of the transgene.
	h.	What is the function of the transgene product?
	i.	Have <i>in vitro</i> expression assays been conducted?  Yes  No
		If "Yes", describe the results:
	j.	Does the host genome possess an endogenous version of the transgene?  Yes No
	k.	State any predicted phenotypic health effects from the transgene on founder animals.
9.	DI	NA construct purification. (Please see DNA preparation guidelines)
	a.	Method of vector purification:
	b.	Restriction enzymes used to isolate construct:
	C.	Briefly describe the method for construct isolation (i.e. gel type, electroelution, method of construct concentration, etc.)
	d.	Please attach results of the following gel showing quantification of your DNA construct. We recommend that you use Gibco mass ladder for quantification.
		<ul> <li>i. the vector prior to restriction digestion</li> <li>ii. the vector and construct after restriction digestion</li> <li>iii. the vector appartment</li> </ul>
1		iii. the isolated construct

iv. appropriate size and quantitation matkers

10. Identification of construct incorporation and expression.			
a.	Method used to determine construct incorporation (i.e. Southern blot, PCR):		
	i. List the reference for the above protocol:		
	ii. Description of the probe or primers:		
b.	Method used to determine transgene expression (i.e. Northern blot, PCR, RIA):		
	i. List the reference for the above protocol:		
	a.		

## FOR CORE USE ONLY

Work Request/Case Number(s):	